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1. Enrollment history by site 
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2. Methods and findings Mortality Endpoint Review Committee 
Method: The end-point review committee included one paediatrician with malaria experience and one 
clinical malariologist. The reviewers assessed the fatal cases independently from the trial investigators, 
and were blinded towards the study drug treatment allocations. All clinical and laboratory data 
(including those from the parasitology reference laboratory) were reviewed, along with the ‘Severe 
Adverse Events’ forms. Cases were only defined when both reviewers independently judged that a 
pathology other than malaria or its acute complications was the main cause of death. 
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Table 1. Cases with pathology other than malaria (or its acute complications) as a likely cause of death. 
Age Gender Relevant details 
6 y  F 
Sudden onset of abdominal pain without fever. Death occurred within three 
hours of symptom onset. Parasitaemia 5/1000 RBC (no pretreatment) 
22 m M Death followed return of consciousness and defervescence 
3 y F Death followed return of consciousness and defervescence 
7 m M 
History of diarrhoea, vomiting and generalized rash. Clinical diagnosis of 
measles. Parasitaemia 8/200 WC (one dose of pyrimethamine-sulfadoxine 
pretreatment) 
3 y M Clinical diagnosis of tetanus. Parasitaemia 3/1000 RBC (no pretreatment) 
11 m F Death followed return of consciousness and defervescence 
21 m M Death followed return of consciousness and defervescence 
5 y F 
Suspected meningitis. Haemophilus influenzae type b isolated from blood 
culture. Parasitaemia 2/1000 RBC (pyrimethamine-sulfadoxine 
pretreatment) 
6 y F Clinical diagnosis of tetanus. Parasitaemia 3/1000 RBC (no pretreatment) 
3 m M 
Clinical diagnosis of mastoiditis. Group A streptococcus isolated from blood 
culture. Parasitaemia 13/1000 RBC (no pretreatment) 
4 y M 
Clinical diagnosis of left-sided pneumonia. Haemophilus influenzae type b 
isolated from blood culture. Parasitaemia 81/200 WC (two doses of quinine 
pretreatment) 
22 m M 
Clinical diagnosis of myositis. Group A streptococcus isolated from blood 
culture. Parasitaemia 2/200 WC (three doses of quinine pretreatment) 
14 m F 
Clinical diagnosis of severe acute malnutrition. Salmonella spp. isolated from 
blood culture. Parasitaemia 1/200 WC (no pretreatment) 
6 m M 
Clinical diagnosis of severe cellulitis. Group A streptococcus isolated from 
blood culture. Parasitaemia 1/500 WC (six doses of artemether-lumefantrine 
pretreatment) 
16 m M 
Clinical observation of pustular rash and impetigo (no coma). Staphylococcus 
aureus isolated from blood culture. Parasitaemia 3/200 WC (one dose of 
amodiaquine pretreatment) 
14 m M Death followed return of consciousness and defervescence 
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3.  Methods Neurological Endpoint Committee 
Neurological sequelae were divided into 4 functional domains or systems, including motor deficits, 
vision deficits, hearing and speech deficits and persisting seizures. Severity of the deficits was graded 
according to the tables below. In case a patient had a pathological entry in 2 or more functional 
domains, the deficit with the most severe grade was moved up one ‘severity grade’  if the ‘severe’ grade 
had not yet been reached  (Example 1: cerebellar ataxia (severe) + speech difficulties (mild) = total grade 
is severe. Example 2: Facial nerve palsy (moderate) + speech difficulties (mild) = total grade is severe). In 
case the clinical record form mentioned a pre-existing neurological problem and there was no significant 
deterioration of symptoms during the malaria episode, the neurological problems were not considered 
as being sequelae of the acute disease episode.  
FUNCTIONAL SYSTEMS TABLES 
1) MOTOR 
CRF Entry MILD MODERATE SEVERE 
Monoparesis  x  
Hemiplegia/paresis    x  
Quadriparesis   x 
Continued posturing   x 
Hypotonia  x      
Extrapyramidal rigidity   x 
Cerebellar Ataxia   x 
Gait * unsteady x   
Gait* hemiplegic/ataxic   x 
Gait* unable to walk   x 
Cranial nerve palsies  x  
Facial nerve palsy  x  
* Gait was considered only in children > 18 months 
IF there is more than one pathological entry within the motor system: the most severe grading prevails. 
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2) VISION 
CRF entry MILD MODERATE SEVERE 
Blindness bilateral   x 
Blindness unilateral  x  
Some impairment  bilateral  x  
Some impairment unilateral x   
 
3) HEARING and SPEECH 
CRF entry MILD MODERATE SEVERE 
Deafness bilateral   X 
Deafness unilateral  x  
Possible impairment bilateral  x  
Possible impairment unilateral x   
Speech difficulties* x   
Unable to speak*   X 
*Speech was assessed only in children > 18 months 
 4) SEIZURES 
In patients with no previous history of seizures: 
Any seizures - moderate 
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4. Quality assessment of artesunate batches used in the trial 
LC-MS/MS Analysis of the artesunate content in vials for injection 
 
Methods1:  
From each batch, 3 vials were selected for testing. Each vial’s content was quantified using 3 replicate 
measurements. Samples were quantified using a standard curve constructed from 3 replicate samples at 
each calibration level (concentrations 19.2, 24.0, 28.8 ng/ml). Results for each vial and a batch average 
were summarized. 
Sample preparation: 
The content of each vial to be tested was reconstituted in 1.0-1.5 mL ethanol. The whole amount was 
transferred into a 250 ml volumetric flask thereby diluting the solution to 240 µg/ml (assuming initial 
content as stated; 60 mg). This solution was further diluted using volumetric flasks to a final 
approximate concentration of 24 ng/ml.  
Quantification: 
Samples were quantified using an API 5000 triple quadrupole mass spectrometer (Applied 
Biosystems/MDS SCIEX, Foster City, USA). The final sample was injected into the LC-MS/MS system 
equipped with a TurboV ionization source (TIS) interface operated in the positive ion mode. 
Quantification was performed using selected reaction monitoring (SRM) for the transition m/z 402 – 
163.  
Results: The following results (table 1) were obtained for the different batches.  
Conclusion: all tested vials’ contents come within GMP specification of +/- 10% of stated content.  
Reference. 
Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, Day NP, Lindegardh N. A 
liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its 
metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 
876: 61-8. 
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Site Batch Expire pha ID ARS (mg/vial) Amount (%) Average (%) 
Batch 
average 
(%) 
Mozambique 60109 Dec-08 A1 1 57.00 95.00 95.28 95.28 
   
A1 2 57.25 95.42 
  
   
A1 3 57.25 95.42 
  
 
ZA070701 Jun-10 B1 1 58.00 96.67 96.94 93.79 
   
B1 2 58.25 97.08 
  
   
B1 3 58.25 97.08 
  
   
B2 1 54.00 90.00 90.00 
 
   
B2 2 54.25 90.42 
  
   
B2 3 53.75 89.58 
  
   
B3 1 56.75 94.58 94.44 
 
   
B3 2 56.25 93.75 
        B3 3 57.00 95.00     
Kenya ZA060903 Aug-09 C1 1 55.50 92.50 92.50 93.84 
   
C1 2 55.25 92.08 
  
   
C1 3 55.75 92.92 
  
   
C2 1 57.50 95.83 95.28 
 
   
C2 2 56.75 94.58 
  
   
C2 3 57.25 95.42 
  
   
C3 1 56.00 93.33 93.75 
 
   
C3 2 56.25 93.75 
        C3 3 56.50 94.17     
Tanzania 
Korogwe ZA070406 Mar-10 D1 1 56.25 93.75 92.36 91.53 
 
  
D1 2 54.75 91.25 
  
 
  
D1 3 55.25 92.08 
  
 
  
D2 1 54.25 90.42 90.55 
 
 
  
D2 2 54.25 90.42 
  
 
  
D2 3 54.50 90.83 
  
 
  
D3 1 55.50 92.50 91.67 
 
 
  
D3 2 54.50 90.83 
        D3 3 55.00 91.67     
Tanzania 
Muheza ZA070406 Mar-10 E1 1 62.25 103.75 102.78 98.15 
   
E1 2 61.25 102.08 
  
   
E1 3 61.50 102.50 
  
   
E2 1 55.25 92.08 91.80 
 
   
E2 2 54.50 90.83 
  
   
E2 3 55.50 92.50 
  
   
E3 1 60.00 100.00 99.86 
 
   
E3 2 60.00 100.00 
        E3 3 59.75 99.58     
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Site Batch Expire pha ID ARS (mg/vial) Amount (%) Average (%) 
Batch 
average 
(%) 
The Gambia ZA060203 Jan-09 F1 1 58.75 97.92 97.78 96.76 
   
F1 2 58.25 97.08 
  
   
F1 3 59.00 98.33 
  
   
F2 1 59.75 99.58 100.00 
 
   
F2 2 59.75 99.58 
  
   
F2 3 60.50 100.83 
  
   
F3 1 55.50 92.50 92.50 
 
   
F3 2 55.25 92.08 
        F3 3 55.75 92.92     
Uganda ZA070406 Mar-10 G1 1 59.75 99.58 100.14 92.50 
   
G1 2 60.25 100.42 
  
   
G1 3 60.25 100.42 
  
   
G2 1 55.25 92.08 92.08 
 
   
G2 2 55.50 92.50 
  
   
G2 3 55.00 91.67 
  
   
G3 1 51.25 85.42 85.28 
 
   
G3 2 50.75 84.58 
        G3 3 51.50 85.83     
Nigeria ZA070701 Jun-10 H1 1 54.75 91.25 91.39 92.31 
   
H1 2 54.50 90.83 
  
   
H1 3 55.25 92.08 
  
   
H2 1 57.50 95.83 96.39 
 
   
H2 2 58.00 96.67 
  
   
H2 3 58.00 96.67 
  
   
H3 1 53.75 89.58 89.17 
 
   
H3 2 53.25 88.75 
        H3 3 53.50 89.17     
Rwanda ZA070701 Jun-10 I1 1 58.75 97.92 97.64 95.00 
   
I1 2 58.25 97.08 
  
   
I1 3 58.75 97.92 
  
   
I2 1 55.00 91.67 92.50 
 
   
I2 2 55.50 92.50 
  
   
I2 3 56.00 93.33 
  
   
I3 1 56.75 94.58 94.86 
 
   
I3 2 57.25 95.42 
        I3 3 56.75 94.58     
DRC LA091001 10-08-12 J1 1 57.25 95.42 95.00 95.88 
   
J1 2 57.25 95.42 
  
   
J1 3 56.50 94.17 
  
   
J2 1 57.50 95.83 96.25 
 
   
J2 2 58.00 96.67 
  
   
J2 3 57.75 96.25 
  
   
J3 1 57.50 95.83 96.39 
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5. Quality assessment of quinine batches used in the trial 
 
LC-UV Analysis of Quinine content in vials for injection 
 
Methods (modified from ref. 1):  
From each batch, 3 vials were selected for testing. Each vial’s content was quantified using 3 replicate 
measurements. Samples were quantified using a standard curve constructed from 3 replicate samples at 
each calibration level (concentrations 15.7, 19.6 and 23.4 µg/ml). Results for each vial and a batch 
average were summarized. 
 
Sample preparation: 
The content of each vial to be tested was transferred into a 100 ml volumetric flask thereby diluting the 
solution to 6.00 mg/ml (assuming initial content 600 mg). Exactly 1000 µl of this solution was further 
diluted using a 250 ml volumetric flask to a final approximate concentration of 19.6 µg/ml.  
 
Quantification: 
Samples were quantified using a LaChrom Elite LC-UV system (Hitachi, Tokyo, Japan). Quantification was 
performed at the wavelength 250 nm.  
 
Results: The following results (table 1) were obtained for the different batches.  
 
Conclusion: all tested vials contained between 105-112% of stated content.  
 
Reference. 
1. Newton PN, Keeratithakul D, Teja-Isavadharm P, Pukrittayakamee S, Kyle D, White NJ. 
Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. 
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93:69–72. 
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Site Batch Expire pha ID QN (mg/vial) Amount (%) Average (%) Batch average (%) 
Mozambique 396 Mar-10 A1 1 627.56 104.59 105.42 106.06
A1 2 634.11 105.68
A1 3 635.94 105.99
A2 1 633.62 105.60 106.58
A2 2 643.05 107.17
A2 3 641.76 106.96
A3 1 631.20 105.20 106.16
A3 2 633.65 105.61
A3 3 646.11 107.68
397 Sep-10 B1 1 641.64 106.94 108.58 108.71
B1 2 667.79 111.30
B1 3 645.01 107.50
B2 1 635.42 105.90 107.38
B2 2 641.58 106.93
B2 3 655.88 109.31
B3 1 651.68 108.61 110.17
B3 2 672.84 112.14
B3 3 658.60 109.77
Kenya 397 Sep-10 C1 1 639.47 106.58 108.21 108.50
C1 2 650.55 108.42
C1 3 657.74 109.62
C2 1 646.35 107.73 108.98
C2 2 654.01 109.00
C2 3 661.30 110.22
C3 1 643.29 107.22 108.30
C3 2 658.85 109.81
C3 3 647.33 107.89
Korogwe 396 Mar-10 D1 1 626.94 104.49 105.60 105.13
D1 2 636.01 106.00
D1 3 637.81 106.30
D2 1 620.57 103.43 104.62
D2 2 624.74 104.12
D2 3 637.93 106.32
D3 1 625.14 104.19 105.18
D3 2 635.06 105.84
D3 3 632.97 105.50
Muheza 396 Mar-10 E1 1 638.67 106.44 107.56 106.11
E1 2 643.41 107.24
E1 3 647.27 107.88
E2 1 632.42 105.40 106.11
E2 2 638.76 106.46
E2 3 638.85 106.48
E3 1 627.80 104.63 105.04
E3 2 634.23 105.70
E3 3 628.72 104.79
398 Sep-10 F1 1 663.25 110.54 111.24 111.00
F1 2 673.82 112.30
F1 3 665.31 110.88
F2 1 654.80 109.13 110.55
F2 2 672.38 112.06
F2 3 662.80 110.47
F3 1 660.68 110.11 111.20
F3 2 666.26 111.04
F3 3 674.71 112.45
The Gambia 396 Mar-10 G1 1 661.39 110.23 112.04 107.14
G1 2 676.70 112.78
G1 3 678.56 113.09
G2 1 620.76 103.46 104.40
G2 2 622.04 103.67
G2 3 636.37 106.06
G3 1 624.25 104.04 104.99
G3 2 627.28 104.55
G3 3 638.33 106.39
Uganda 396 Mar-10 H1 1 628.72 104.79 106.29 105.96
H1 2 631.81 105.30
H1 3 652.75 108.79
H2 1 628.50 104.75 105.30
H2 2 629.70 104.95
H2 3 637.26 106.21
H3 1 625.23 104.20 106.30
H3 2 649.94 108.32
H3 3 638.15 106.36
399 Sep-10 I1 1 658.82 109.80 110.60 111.91
I1 2 663.38 110.56
I1 3 668.64 111.44
I2 1 658.66 109.78 111.64
I2 2 664.91 110.82
I2 3 685.88 114.31
I3 1 672.41 112.07 113.49
I3 2 676.39 112.73
I3 3 694.09 115.68
Nigeria 396 Mar-10 J1 1 627.28 104.55 105.63 105.34
J1 2 638.18 106.36
J1 3 635.85 105.98
J2 1 628.78 104.80 105.86
J2 2 628.84 104.81
J2 3 647.92 107.99
J3 1 620.05 103.34 104.52
J3 2 627.49 104.58
J3 3 633.77 105.63
Rwanda 396 Mar-10 K1 1 620.12 103.35 104.12 104.03
K1 2 622.17 103.69
K1 3 631.87 105.31
K2 1 614.24 102.37 103.55
K2 2 620.85 103.48
K2 3 628.78 104.80
K3 1 619.29 103.21 104.43
K3 2 627.59 104.60
K3 3 632.82 105.47
397 Sep-10 L1 1 639.59 106.60 107.30 107.26
L1 2 636.53 106.09
L1 3 655.20 109.20
L2 1 635.09 105.85 107.00
L2 2 639.13 106.52
L2 3 651.80 108.63
L3 1 636.46 106.08 107.49
L3 2 645.34 107.56
L3 3 653.03 108.84  
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6. Assessing pre-treatment: Classification of the efficacy of antimalarial drugs 
 
Table 2.  
Classification of antimalarials according to likely efficacy for the treatment of uncomplicated falciparum 
malaria in West Africa (Ghana, The Gambia, Nigeria) or the regions corresponding to the other 
AQUAMAT study sites. In the main paper, intermediate- efficacy and ineffective antimalarial drugs are 
grouped together as one category. 
 
 
Efficacy of pre-treatment: yes (y), no (n), intermediate (i) 
 
Ghana, Gambia or Nigeria Other study sites 
quinine injection y y 
artemether injection y y 
artesunate/artemether tabs y y 
sulphadoxin-pyrimethamine (SP) i n 
SP-amodiaquine y i 
chloroquine n n 
amodiaquine y i 
artemether-lumefantrine y y 
artesunate suppository y y 
artesunate-amodiaquine y y 
artemether-amodiaquine y y 
artemether-quinine y y 
dihydroartemisinin (DHA) y y 
DHA-amodiaquine y y 
SP-artemether-lumefantrine y y 
pyrimethamine-sulphamethopirazine i n 
 
13 
 
7.  National and Sponsor Ethics Committee/Institutional Review Board (EC/IRB) approval documents 
 for the AQUAMAT trial 
Country Study Site Ethical Review 
Board 
Address of ERB Reference 
Number 
Document Date 
DRC Kinshasa ESP UNIKIN 
Comité 
d'Ethique 
Université de Kinshasa 
Faculté de Médecine 
BP 11850 Kinshasa 
DRC 
ESP/CE/050/ 
2009 
Approval 24/09/2009 
DRC Kinshasa   ESP/CE/050B/
2009 
Revision 28/12/2009 
Ghana Kumasi Committee for 
Human 
Research 
Publications and 
Ethics 
IRB00001567 
University Office 
Kumasi  
Ghana 
 
CHRPE/01/01
/06 
Approval 23/01/2006 
Ghana Kumasi   CHRPE/01/01
/06 
Renewal 22/05/2009 
Kenya Kilifi KEMRI/ 
National Ethical 
Review 
Committee 
KEMRI  
PO Box 54840 
00200 Nairobi 
Kenya 
SSC Protocol 
No  974 
KEMRI/RES/ 
7/3/1 
Approval 21/10/2005 
Kenya Kilifi   KEMRI/RES/ 
7/3/1 
Renewal 29/07/2008 
Kenya Kilifi   KEMRI/RES/ 
7/3/1 
Renewal 06/07/2009 
Kenya Kilifi   KEMRI/RES/ 
7/3/1 
Renewal 18/08/2010 
Kenya Kilifi   KEMRI/RES/ 
7/3/1 
Revision 10/07/2008 
Kenya Kilifi   KEMRI/RES/ 
7/3/1 
Revision 21/05/2010 
The Gambia Banjul The Gambia 
Government/ 
MRC 
Laboratories 
Joint Ethics 
Committee 
c/o Laboratories 
Fajara PO Box 273  
Banjul  
The Gambia 
 
SCC1012 Approval 30/09/2005 
Rwanda Rwamagana Rwanda 
National Ethics 
Committee 
(RNEC) 
IRB00001497/ 
FWA000001973 
Ministry of Health PO 
Box 84 Kigali  
Rwanda 
72/RNEC/ 
2009 
Approval 03/04/2008 
Rwanda Rwamagana   72/RNEC/ 
2009 
Renewal 18/06/2009 
Rwanda Rwamagana   127/RNEC/ 
2009 
Revision 02/11/2009 
Rwanda Nyanza   127/RNEC/ Approval 02/11/2009 
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Country Study Site Ethical Review 
Board 
Address of ERB Reference 
Number 
Document Date 
2009 
Nigeria Ilorin University of 
Ilorin Teaching 
Hospital Ethical 
Review 
Committee 
IRB00002974 
PMB 1459 Ilorin 
Kwara State 
Nigeria 
 
UITH/CAT/18
9/10/659 
Approval 26/10/2007 
Nigeria Ilorin   UITH/CAT/18
9/10/659 
Revision 14/02/2010 
Mozambique Beira Comité Nacional 
de Bioética para 
a Saúde IRB 
00002657 
Ministério da Saúde  
C Postal 264  
Av Eduardo 
Mondlane/Salvador 
Allende  
Maputo 
Moçambique 
52/CNBS/05 Approval 23/06/2005 
Mozambique Beira   105/CNBS/07 Revision 04/06/2007 
Tanzania Korogwe/ 
Muheza 
Tanzania 
Medical 
Research 
Coordinating 
Committee 
(MRCC) 
National Institute for 
Medical Research 
P O Box 9653  
Dar es Salaam 
Tanzania 
 
NIMR/HQ/R 
8a/Vol IX/435 
Approval 29/05/2006 
Tanzania  
 
Korogwe/ 
Muheza 
  NIMR/HQ/R 
8c/Vol IX/527  
Renewal 26/02/2007 
Tanzania Korogwe/ 
Muheza 
  NIMR/HQ/R 
8c/Vol I/22 
Revision 20/04/2007 
Tanzania Korogwe/ 
Muheza 
  NIMR/HQ/R 
8c/Vol I/60 
Revision 15/08/2008 
Uganda Mbarara Uganda 
National Council 
for Science and 
Technology 
FWA 00001293 
Plot 6  
Kimera Road, Ntinda  
PO Box 6884 
Kampala 
Uganda 
HS 349 Approval 26/09/2007 
Uganda Mbarara   HS 349 Renewal 05/09/2008 
Uganda Mbarara   HS 349 Renewal 31/08/2009 
Uganda Mbarara   HS 349 Revision 04/01/2010 
UK Oxford University of 
Oxford OXTREC 
University of Oxford  
Manor House 
The John Radcliffe 
Oxford OX3 9DZ 
United Kingdom 
 
034-02 Approval 24/05/2005 
UK Oxford   034-02 Revision 03/10/2007 
UK Oxford   034-02 Revision 02/06/2008 
UK Oxford   034-02 Revision 11/08/2008 
UK Oxford   034-02 Revision 16/02/2009 
UK Oxford   034-02 Revision 09/03/2009 
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Country Study Site Ethical Review 
Board 
Address of ERB Reference 
Number 
Document Date 
UK Oxford   034-02 Revision 18/03/2009 
UK Oxford   034-02 Revision 08/06/2009 
UK Oxford   034-02 Revision 29/09/2009 
UK Oxford   034-02 Renewal 02/02/2010 
 
